Journal of Clinical Oncology, Vol 23, No 2 (January 10), 2005: pp. 254-266
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.09.112
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Andrew J. Dannenberg,
Scott M. Lippman,
Jason R. Mann,
Kotha Subbaramaiah,
Raymond N. DuBois
From the Department of Medicine, Weill Medical College of Cornell University, New York, NY; Departments of Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Departments of Medicine, Cancer Biology, and Cell & Developmental Biology, Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center, Nashville, TN
Address reprint requests to Raymond N. DuBois, MD, PhD, Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, 2300 Pierce Avenue, Nashville, TN 37232-6838; e-mail: raymond.dubois{at}vanderbilt.edu.
Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.
Supported by the United States Public Health Service Grants RO1-DK-62112, R01-CA82578, R01-89578, PO1-CA77839 and P01-CA106451. A.J.D. is the Henry R. Erle, M.D.-Roberts Family Professor of Medicine. R.N.D. is the Hortense B. Ingram Professor of Molecular Oncology and the recipient of a National Institutes of Health MERIT award (R37-DK47297).
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D.G. Power and D.H. Ilson
Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers
Therapeutic Advances in Medical Oncology,
November 1, 2009;
1(3):
145 - 165.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell Carcinoma
Cancer Prevention Research,
September 1, 2009;
2(9):
823 - 829.
|
|
|
|
|
|
|
Y. M. Kim, S.-Y. Park, and H. Pyo
Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells
Mol. Cancer Res.,
August 1, 2009;
7(8):
1367 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila
The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Experimental Biology and Medicine,
July 1, 2009;
234(7):
713 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Husvik, C. Khuu, M. Bryne, and T.S. Halstensen
PGE2 Production in Oral Cancer Cell Lines is COX-2-dependent
Journal of Dental Research,
February 1, 2009;
88(2):
164 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res.,
January 15, 2009;
15(2):
425 - 430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind
Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
Cancer Prevention Research,
January 1, 2009;
2(1):
27 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Subbaramaiah, R. Benezra, C. Hudis, and A. J. Dannenberg
Cyclooxygenase-2-derived Prostaglandin E2 Stimulates Id-1 Transcription
J. Biol. Chem.,
December 5, 2008;
283(49):
33955 - 33968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhang, N. Bhola, S. Kalyankrishna, W. Gooding, J. Hunt, R. Seethala, J. R. Grandis, and J. M. Siegfried
Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas
Mol. Cancer Res.,
December 1, 2008;
6(12):
1946 - 1956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lurje, F. Nagashima, W. Zhang, D. Yang, H. M. Chang, M. A. Gordon, A. El-Khoueiry, H. Husain, P. M. Wilson, R. D. Ladner, et al.
Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
Clin. Cancer Res.,
December 1, 2008;
14(23):
7884 - 7895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Anand, A. B. Kunnumakkara, K. B. Harikumar, K. S. Ahn, V. Badmaev, and B. B. Aggarwal
Modification of Cysteine Residue in p65 Subunit of Nuclear Factor-{kappa}B (NF-{kappa}B) by Picroliv Suppresses NF-{kappa}B-Regulated Gene Products and Potentiates Apoptosis
Cancer Res.,
November 1, 2008;
68(21):
8861 - 8870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Howe and S. M. Lippman
Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
J Natl Cancer Inst,
October 15, 2008;
100(20):
1420 - 1423.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Wirth, J. F. Krane, Y. Li, M. Othus, A. E. Moran, D. M. Dorfman, C. M. Norris Jr, L. Goguen, M. R. Posner, R. I. Haddad, et al.
A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions
Cancer Prevention Research,
October 1, 2008;
1(5):
339 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Brown, K. Subbaramaiah, A. P. Salmon, R. Baker, R. A. Newman, P. Yang, X. K. Zhou, R. P. Bissonnette, A. J. Dannenberg, and L. R. Howe
Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor-Selective Retinoid
Cancer Prevention Research,
August 1, 2008;
1(3):
208 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wang, R. R. Seethala, Q. Zhang, W. Gooding, C. van Waes, H. Hasegawa, and R. L. Ferris
Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy
J Natl Cancer Inst,
April 2, 2008;
100(7):
502 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma
Neuro-oncol,
April 1, 2008;
10(2):
190 - 198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Visscher, V. S. Pankratz, M. Santisteban, C. Reynolds, A. Ristimaki, R. A. Vierkant, W. L. Lingle, M. H. Frost, and L. C. Hartmann
Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer
J Natl Cancer Inst,
March 19, 2008;
100(6):
421 - 427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L C Huber, P Kunzler, S H Boyce, B A Michel, R E Gay, B S Ink, and S Gay
Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts
Ann Rheum Dis,
March 1, 2008;
67(3):
389 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Choi and J.N. Myers
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Journal of Dental Research,
January 1, 2008;
87(1):
14 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zhang, J. Li, L. Song, W. Ouyang, J. Gao, and C. Huang
A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression
Mol. Cancer Res.,
January 1, 2008;
6(1):
165 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al.
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
J. Clin. Oncol.,
November 1, 2007;
25(31):
4887 - 4894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence
Clin. Cancer Res.,
October 1, 2007;
13(19):
5965 - 5973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell
The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2007;
16(7):
1330 - 1340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin
Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res.,
May 15, 2007;
13(10):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zhang, J. Li, K. Wu, W. Ouyang, J. Ding, Z.-g. Liu, M. Costa, and C. Huang
JNK1, but not JNK2, is required for COX-2 induction by nickel compounds
Carcinogenesis,
April 1, 2007;
28(4):
883 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Chan, J. E. Manson, D. Feskanich, M. J. Stampfer, G. A. Colditz, and C. S. Fuchs
Long-term Aspirin Use and Mortality in Women
Arch Intern Med,
March 26, 2007;
167(6):
562 - 572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Clin. Cancer Res.,
March 1, 2007;
13(5):
1611 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
Clin. Cancer Res.,
February 1, 2007;
13(3):
1036 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ding, X. Zhang, J. Li, L. Song, W. Ouyang, D. Zhang, C. Xue, M. Costa, J. A. Melendez, and C. Huang
Nickel Compounds Render Anti-apoptotic Effect to Human Bronchial Epithelial Beas-2B Cells by Induction of Cyclooxygenase-2 through an IKKbeta/p65-dependent and IKK{alpha}- and p50-independent Pathway
J. Biol. Chem.,
December 22, 2006;
281(51):
39022 - 39032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lilenbaum, M. A. Socinski, N. K. Altorki, L. L. Hart, R. S. Keresztes, S. Hariharan, M. E. Morrison, R. Fayyad, and P. Bonomi
Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
October 20, 2006;
24(30):
4825 - 4832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Landolfi and K. A. Terio
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Vet. Pathol.,
September 1, 2006;
43(5):
674 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan, and C. Huang
Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells
J. Biol. Chem.,
August 25, 2006;
281(34):
24405 - 24413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
J. Immunol.,
August 15, 2006;
177(4):
2391 - 2402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Park, H. J. Jun, M. J. Cho, K. H. Cho, J. S. Lee, J. I. Zo, and H. Pyo
Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer Cells.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4989 - 4999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carothers, A. E. Moran, N. L. Cho, M. Redston, and M. M. Bertagnolli
Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.
Cancer Res.,
June 15, 2006;
66(12):
6432 - 6438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res.,
June 15, 2006;
12(12):
3661 - 3697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Reckamp, K. Krysan, J. D. Morrow, G. L. Milne, R. A. Newman, C. Tucker, R. M. Elashoff, S. M. Dubinett, and R. A. Figlin
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3381 - 3388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats.
Cancer Res.,
April 15, 2006;
66(8):
4542 - 4546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Huh, A. Liepins, J. Zielonka, C. Andrekopoulos, B. Kalyanaraman, and A. Sorokin
Cyclooxygenase 2 Rescues LNCaP Prostate Cancer Cells from Sanguinarine-Induced Apoptosis by a Mechanism Involving Inhibition of Nitric Oxide Synthase Activity.
Cancer Res.,
April 1, 2006;
66(7):
3726 - 3736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Miller, V. A. Patel, and A. Sorokin
Cyclooxygenase-2 Rescues Rat Mesangial Cells from Apoptosis Induced by Adriamycin via Upregulation of Multidrug Resistance Protein 1 (P-Glycoprotein)
J. Am. Soc. Nephrol.,
April 1, 2006;
17(4):
977 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lippman and J. J. Lee
Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Cancer Res.,
March 15, 2006;
66(6):
2893 - 2903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori
FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression.
Cancer Res.,
March 1, 2006;
66(5):
2683 - 2690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Thiel, M. Heinonen, J. Rintahaka, T. Hallikainen, A. Hemmes, D. A. Dixon, C. Haglund, and A. Ristimaki
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells
J. Biol. Chem.,
February 24, 2006;
281(8):
4564 - 4569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Holla, J. R. Mann, Q. Shi, and R. N. DuBois
Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer
J. Biol. Chem.,
February 3, 2006;
281(5):
2676 - 2682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol.,
December 20, 2005;
23(36):
9063 - 9066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wu, R. A. Silbajoris, Y. E. Whang, L. M. Graves, P. A. Bromberg, and J. M. Samet
p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression
Am J Physiol Lung Cell Mol Physiol,
November 1, 2005;
289(5):
L883 - L889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Peek Jr., S. Mohla, and R. N. DuBois
Inflammation in the Genesis and Perpetuation of Cancer: Summary and Recommendations from a National Cancer Institute-Sponsored Meeting
Cancer Res.,
October 1, 2005;
65(19):
8583 - 8586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Wirth, R. I. Haddad, N. I. Lindeman, X. Zhao, J. C. Lee, V. A. Joshi, C. M. Norris Jr, and M. R. Posner
Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol.,
October 1, 2005;
23(28):
6976 - 6981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, and E. C. degli Uberti
Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated Mechanism
J. Clin. Endocrinol. Metab.,
October 1, 2005;
90(10):
5754 - 5760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark, C. Namgyal, T. Kawasaki, K. Kinsella, A. L. Michelini, P. C. Enzinger, et al.
Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
Clin. Cancer Res.,
September 15, 2005;
11(18):
6650 - 6656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Reddy, J. M. Patlolla, B. Simi, S.H. Wang, and C. V. Rao
Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase Inhibitor, Administered in Diet Rich in {omega}-3 Polyunsaturated Fatty Acids
Cancer Res.,
September 1, 2005;
65(17):
8022 - 8027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Choe, X. Zhang, H. J. C. Shin, D. M. Shin, and Z. Chen
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer
Mol. Cancer Ther.,
September 1, 2005;
4(9):
1448 - 1455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lippman, N. Gibson, K. Subbaramaiah, and A. J. Dannenberg
Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways
Clin. Cancer Res.,
September 1, 2005;
11(17):
6097 - 6099.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist,
September 1, 2005;
10(8):
590 - 601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Du, N. K. Altorki, L. Kopelovich, K. Subbaramaiah, and A. J. Dannenberg
Tobacco Smoke Stimulates the Transcription of Amphiregulin in Human Oral Epithelial Cells: Evidence of a Cyclic AMP-Responsive Element Binding Protein-Dependent Mechanism
Cancer Res.,
July 1, 2005;
65(13):
5982 - 5988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Banerjee, I. Bhattacharyya, and J. K. Vishwanatha
Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Mol. Cancer Ther.,
June 1, 2005;
4(6):
865 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol.,
May 10, 2005;
23(14):
3186 - 3197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lippman, J. Sudbo, and W. K. Hong
Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development
J. Clin. Oncol.,
January 10, 2005;
23(2):
346 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
